When applied topically, particularly to large areas, when the skin is broken, or under occlusive dressings, or when given intranasally, corticosteroids may be absorbed in sufficient amounts to cause systemic effects . For recommendations concerning the correct use of corticosteroids on the skin, and a rough guide to the clinical potencies of topical corticosteroids please consult your pharmacist..
A nasal suspension of mometasone furoate 0.05% (Momate AZ, with Azenate in Kenya), as the monohydrate, is given in the treatment and prophylaxis of the symptoms of allergic rhinitis. The usual adult dose is the equivalent of 100 micrograms of mometasone furoate in each nostril once daily, increased if necessary to 200 micrograms in each nostril daily. Once symptoms are controlled a dose of 50 micrograms in each nostril daily may be effective for maintenance. In the UK, the dose for children aged between 6 and 11 years is the equivalent of 50 micrograms in each nostril once daily. In the USA, similar doses may be given to treat allergic rhinitis in children from 2 years of age.
The nasal suspension is also given for the treatment of nasal polyps in patients 18 years and older; the recommended initial dose in the UK is 100 micrograms into each nostril once daily, increased after 5 to 6 weeks to twice daily if needed. In the USA the recommended initial dose is 100 micrograms in each nostril twice daily, although once daily administration may be sufficient in some patients.
Mometasone furoate is used by dry powder inhaler for the prophylaxis of asthma in Kenya. An initial dose for mild to moderate asthma is 400 micrograms once daily. The dose may be adjusted to a maintenance dose of 200 micrograms inhaled once or twice daily. In severe asthma an initial dose of 400 micrograms twice daily is used, then titrated to the lowest effective dose once symptoms are controlled.